CD29 Antikörper

Antigen: CD29

Klonalität: Monoklonal (MEM-101A)

Wirt: Maus

Reaktivität: Human, Schwein, Hund

Applikation: Durchflusszytometrie (FACS), Immunpräzipitation (IP), Western Blot (WB)

Produktnummer: ABIN94054

Produktbeschreibung

Immunogen: Raji Burkitt's lymphoma cell line

Format: Purified

Isotyp: IgG1  (Passende Sekundärantikörper)

Klon: MEM-101A

Beschreibung: CD29 (beta1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least6 different alpha chains (alpha1-alpha6, CD49a-f) determining the binding properties ofbeta1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, lamininand other extracellular matrix (ECM) components. This interaction hinders cell death,whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of mostbeta1 integrins correlates with acquiring multidrug resistance of tumour cells duringselection in presence of antitumour drug. In platelets, translocation of intracellular pool ofbeta1 integrins to the plasma membrane following thrombin stimulation. These integrins arealso up-regulated in leukocytes during emigration and extravascular migration and appear tobe critically involved in regulating the immune cell trafficking from blood to tissue, as well asin regulating tissue damage and disease symptoms related to inflammatory bowel disease.Through a beta1 integrin-dependent mechanism, fibronectin and type I collagen enhancecytokine secretion of human airway smooth muscle in response to IL-1beta.

Spezifität: The antibody MEM-101A reacts with CD29 (integrin beta1 chain), a 130 kDa single chaintype I glycoprotein expressed as a heterodimer (non-covalently associated with the integrinalpha subunits 1-6). CD29 is broadly expressed on majority of hematopoietic andnon-hematopoietic cells (leukocytes, platelets, fibroblasts, endothelial cells, epithelial cellsand mast cells).HLDA VI, WS Code AS A048 This antibody does not react with: Mouse.

Kommentare:

CD29 (b1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 dibberent a chains (a1-a6, CD49a-f) determining the binding properties of b1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most b1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of b1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a b1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1b.

Anwendungen

Applikationshinweise: Western Blotting - Recommended dilution: 2 µg/ml. Positive control: JURKAT human leukemia T-cell lysateKg-1a human leukemia cell lysate. Sample preparation: buffer with laurylmaltoside, 2 x non-reducing SDS. Application note: Non-reducing conditions. SDS-PAGE (6% separating gel, 4% stacking gel). Recommended secondary antibody - anti mouse IgG/HRP, dilution 1: 2000, 60 min onvertical incubator.

Konzentration: 1 mg/ml

Reinheit: > 95% (by SDS-PAGE)

Reinigung: Purified from ascites by protein-A affinity chromatography.

Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Lagerung: Store at 2-8 o C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20 o C. Avoid freeze/thaw cycles.

Forschungsgebiet: CD Antigene, Oberflächenrezeptoren der Immunzellen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

Western Blotting analysis (non-reducing conditions) of isolated peripheral blood lymphocytes of various species using anti-CD29 (MEM-101A). Lane 1: lysate of human PBL. Lane 2: lysate of canine PBL. Lane 3: lysate of porcine PBL

Publikationen

Publikationen: Kim, Cho: "Regulatory role of ginsenoside Rp1, a novel ginsenoside derivative, on CD29-mediated cell adhesion." in: Planta medica, Vol. 75, Issue 4, pp. 316-20, 2009 (PubMed).

Handke, Oelschlegel, Franke et al.: "Hantaan virus triggers TLR3-dependent innate immune responses." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 5, pp. 2849-58, 2009 (PubMed).

Lomakina, Knauf, Schultz et al.: "Activation of human neutrophil Mac-1 by anion substitution." in: Blood cells, molecules & diseases, Vol. 42, Issue 3, pp. 177-84, 2009 (PubMed).

Soler, Chapman, Yang et al.: "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases." in: The Journal of pharmacology and experimental therapeutics, Vol. 330, Issue 3, pp. 864-75, 2009 (PubMed).

Wagner, Bork, Horn et al.: "Aging and replicative senescence have related effects on human stem and progenitor cells." in: PLoS ONE, Vol. 4, Issue 6, pp. e5846, 2009 (PubMed).

Byeon, Choi, Hong et al.: "Inhibitory effect of saponin fraction from Codonopsis lanceolata on immune cell-mediated inflammatory responses." in: Archives of pharmacal research, Vol. 32, Issue 6, pp. 813-22, 2009 (PubMed).

Lee, Lee, Cho: "Cell-permeable ceramides act as novel regulators of U937 cell-cell adhesion mediated by CD29, CD98, and CD147." in: Immunobiology, 2009 (PubMed).